CA-XPANSIV-CBL-HOLDING
27.7.2020 15:02:13 CEST | Business Wire | Press release
XCHG , the global marketplace for Intelligent Commodities™, today announced the launch of XSignals , a component of the company’s multi-sided platform that offers unprecedented clarity in the pricing and analysis of digital, ESG-inclusive commodities (d-ESGc ). These price signals—reported directly from open market activity—become benchmarks that enable vital ESG factors to be calculated into global trade.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200727005224/en/
XSignals' initial customers include leading firms engaged in providing trading services to sellers and buyers of digital environmental commodities like Renewable Energy Certificates and Carbon Offsets, with a pipeline of customers from industries making long-term environmental commitments, such as the aviation industry’s CORSIA accord.
“The markets we serve are incredibly dynamic, and our customers need to know where value is being created, as reflected in real-time prices,” said Andy Bose, Head of Ecosystems and Data Partnerships for XCHG. “With the launch of our XSignals platform, we provide an unparalleled understanding of the forces moving commodities markets, giving our customers comprehensive information to inform better decisions."
Inclusive of a broad range of asset classes and offerings, XSignals provides timely, transparent information to support trading, compliance, and risk-management decisions. XSignals translates ESG spot market price data into high-quality reference products, enabling global markets to accurately price ESG factors.
“Our aim in launching XSignals is to enhance the market's understanding of price and value for the broad range of environmental products transacted on our exchange,” Bose said. “We’re offering unique insight into where prices are coming from, empowering a deeper understanding of where value will be in the future.”
XCHG’s first product offerings include market data—trade orders and consummated transactions—in US RECs and international carbon from the company’s spot exchange, CBL Markets . XSignals provides daily data on price, volume, time, market depth, and other key indicators that offer real-time insight into value, as reflected in the marketplace. XSignals also offers access to a historical data set that covers the last 30 months of transactions.
“In order for the global economy to transition to a sustainable trajectory, indicative price signals for ESG factors in food, energy, and materials are needed to direct capital flows over time,” said XCHG CEO Joe Madden. “XSignals provides the foundation for this transition through the consistent, reliable representation of objective value for ESG factors in commodity pricing.”
XCHG plans to deepen the XSignals offering with more capabilities, including tools for data analysis and visualization, allowing customers to both self-serve and take advantage of XCHG’s understanding of how that data will be of maximum value.
“XSignals is another step toward delivering on our mission of more accurately valuing the commodities at the base of the global economy in the century ahead,” said Madden.
About XCHG
Xpansiv CBL Holding Group (XCHG) is the world’s first commodity marketplace built for a data-rich, resource-constrained world. We bring transparency to global markets through innovative, ESG-inclusive commodity products and price information. XCHG.net
View source version on businesswire.com: https://www.businesswire.com/news/home/20200727005224/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
